Laboratory for Molecular Diagnostics
Center for Nephrology and Metabolic Disorders
The KRAS gene encodes an importent protein in signal transduction. In 17-25% of human tumor cells a somatic activating mutation can be found. These mutations make make the cell resistant to GTPase activating peptides.
| Research | Method | Carrier testing |
| Turnaround | 5 days | |
| Specimen type | genomic DNA |
| Clinic | Method | Massive parallel sequencing |
| Turnaround | 25 days | |
| Specimen type | genomic DNA |
| Research | Method | Genomic sequencing of the entire coding region |
| Turnaround | 20 days | |
| Specimen type | genomic DNA |
| Research | Method | Multiplex Ligation-Dependent Probe Amplification |
| Turnaround | 25 days | |
| Specimen type | genomic DNA |
| 1. |
Ahrendt SA et al. (2001) Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. 
|
| 2. |
Andreyev HJ et al. (1997) K-ras mutations in patients with early colorectal cancers.
|
| 3. |
NCBI article NCBI 3845
|
| 4. |
OMIM.ORG article Omim 190070
|
| 5. |
Orphanet article Orphanet ID 122879
|
| 6. |
Wikipedia article Wikipedia EN (KRAS)
|
 |
Copyright © 2005-2024 by Center for Nephrology and Metabolic Disorders, Dr. Mato Nagel, MD Albert-Schweitzer-Ring 32, D-02943 Weißwasser, Germany, Tel.: +49-3576-287922, Fax: +49-3576-287944 Sitemap | Webmail | Disclaimer | Privacy Issues | Website Credits |